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Background: Hepatocellular carcinoma is one of the most common cancers worldwide and its incidence is
reported to be increasing in resource-limited countries. There is a paucity of published data regarding hepatocellular
carcinoma in Tanzania, and the study area in particular. This study describes the clinicopathological profile of
hepatocellular carcinoma in our local setting and highlights the challenging problems in the management of this
disease.
Methods: This was a retrospective study of histopathologically confirmed cases of hepatocellular carcinoma seen at
Bugando Medical Center between March 2009 and February 2013.
Results: A total of 142 patients (M: F = 2.2: 1) were studied representing 4.6% of all malignancies. The median age of
patients was 45 years. Hepatitis B virus infection (66.2%) and heavy alcohol consumption (60.6%) were the most
frequently identified risk factors for hepatocellular carcinoma. The majority of patients (88.0%) presented late with
advanced stages. HBsAg was positive in 66.2% of the patients and Hepatitis C Virus antibody in 16.9%. Thirteen (9.2%)
patients tested positive for HIV infection. Most patients (52.8%) had both right and left lobe involvement. The
trabecular pattern (47.9%) was the most frequent histopathological type. None of patients had curative therapy
because of the advanced nature of the disease. Coagulopathy (45.7%) was the most common complications. The
overall mortality rate was 46.5% and it was significantly associated with comorbidity, HIV positivity, CD4+ count <200
cells/μl, high histological grade, advanced stage of the tumor, presence of distant metastases at the time of diagnosis,
and associated complications (P < 0.001). The overall median duration of hospital stay was 14 days. The majority of
patients (71.1%) were lost to follow-up at the end of the follow-up period.
Conclusions: Hepatocellular carcinoma patients in this region are relatively young at diagnosis and the majority of
them present late with an advanced stage and high rate of distant metastasis. Lack of awareness of the disease, poor
accessibility to healthcare facilities, and lack of screening programs in this region may contribute to advanced disease
at the time of diagnosis. There is a need for early detection, adequate treatment, and proper follow-up to improve
treatment outcome.
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Hepatocellular carcinoma (HCC) is one of the most
common cancers worldwide with approximately 550,000
to 600,000 new HCC cases globally each year [1]. HCC
is the third leading cause of cancer deaths worldwide,
with a prevalence 16 to 32 times higher in developing
countries than in developed countries [1,2]. This cancer
has a heterogeneous geographical distribution based on
the prevalence of risk factors in different parts of the
world. It is frequent in Sub-Saharan Africa and southeast
Asia where it is responsible for a large proportion of
cancer deaths, but is rare in the United States and
Europe [3,4]. The high incidence rate may be related to
the high prevalence of Hepatitis B viral (HBV) infection,
aflatoxin B1 contamination, and some hepatotoxic drugs
[5]. Hepatitis C virus (HCV), cigarette smoking, and al-
cohol are also etiologic agents in this environment [6].
Recently, there is an upsurge of HCC in the United
States due to increased HCV infection [7].
The transformation of hepatocytes to the malignant
phenotype may occur irrespective of the etiological
agents. In the context of increased cellular turnover in-
duced by chronic liver injury and regeneration, the acti-
vation of cellular oncogenes or the inactivation of tumor
suppressor genes are the common denominators con-
tributing to the development of HCC [8]. The oncogenic
mechanism of HBV is thought to be based on genetic
damage associated with chronic inflammation and the
integration of HBV DNA into the host genome [9]. Afla-
toxin B1 has been shown to induce mutations at codon
249 of the P53 tumor suppressor gene, thus providing a
clue to how an environmental factor may contribute to
tumor development at a molecular level [8,10]. HCC is
an asymptomatic and slow-growing malignancy whose
natural history is an extension of underlying cirrhosis
[9]. This tumor is aggressive in black people and associ-
ated with poor prognosis [11,12].
HCC in black Africans carries a particularly grave
prognosis, with average survival times from the onset of
symptoms being as short as 14 weeks [2,13] and, with
very few exceptions, all of the patients surviving for less
than one year. The great majority of the population lives
in rural areas where the incidence of the tumor is higher
than it is in urban areas and where facilities for diagnos-
ing and treating HCC are least adequate. HCC often oc-
curs at a relatively young age in black Africans, and this is
even more evident in those born and growing up in rural
areas. Men are affected far more often than women [13].
The occurrence of HCC at such a high incidence in
resource-limited countries and the advanced stage of the
disease when the patients usually seek medical attention,
as well as the inadequate diagnostic and, more import-
antly, treatment facilities for the tumor, pose an enor-
mous challenge in managing HCC in these countries[2,11-13]. Other major challenges in the longer term
management of HCC in developing countries are pre-
symptomatic detection of the tumor and prevention of
hepatitis virus infections, dietary exposure to aflatoxin
B1, and dietary iron overload - the major causes of HCC
in developing countries [2,13].
The clinical stage of the disease at diagnosis often de-
termines the prognosis and survival rate of a patient
with HCC, with the best outcomes seen in patients diag-
nosed at an early stage [2,12,13]. However, the outcome
of treatment of HCC in our environment has been poor
because the majority of these patients present late to the
hospital with an advanced stage of the disease and only
palliative care is possible [11,12]. This is partly due to a
lack of community awareness on the importance of early
reporting to hospital for the early diagnosis and treat-
ment of this condition.
The prognosis of HCC in Sub-Saharan Africa is gener-
ally poor with patients usually presenting late with an
advanced stage of the disease [11-13]. This is in contrast
to what occurs in Western countries where the disease
is increasingly being diagnosed at an early stage (when it
is amenable to treatment), though regular screening of
those at risk [14].
HCC screening programs have been reported to in-
crease the detection of tumors at earlier stages and re-
duce incidence and mortality related to HCC [13,14]. In
resource-limited countries, however, lack of a screening
program in high-risk individuals poses a great challenge
in the prevention of HCC.
There is a paucity of information regarding hepatocel-
lular carcinoma in Tanzania and the study area in par-
ticular. This is partly due to a lack of published local
data regarding this condition and the lack of cancer
registries in this region. This study was designed to de-
scribe the clinicopathological pattern of HCC and high-
light the challenging problem in the management of this
disease in our local setting.Methods
Study design and setting
This was a five-year retrospective study of histologically
confirmed cases of hepatocellular carcinoma which was
conducted at Bugando Medical Center between April 2008
and May 2013. Bugando Medical Center is a consultant,
referral, and teaching hospital for the Catholic University
of Health and Allied Sciences-Bugando (CUHAS-
Bugando) in the Lake and Western zones of the United
Republic of Tanzania. It is situated along the shores of
Lake Victoria in Mwanza City. It has 1000 beds and serves
as a referral center for tertiary specialist care for a catch-
ment population of approximately 13 million people. The
hospital has a newly established oncology department
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ally proven cancers, including hepatocellular carcinoma.
Study population
The study population included all patients who pre-
sented to Bugando Medical Center with histologically
confirmed hepatocellular carcinoma during the study
period. Patients with incomplete data were excluded
from the study. The details of patients were obtained
from patients’ files kept in the medical record depart-
ment, the medical and surgical wards, operating theatre,
and histopathology laboratory. Information collected in-
cluded sociodemographic data, clinical presentation, risk
factors for HCC, investigations, anatomical site, macro-
scopic appearance, tumor stage, histopathological type
and grade, presence of distant metastasis, treatment mo-
dalities, and outcome and follow-up.
Information on risk factors for chronic liver disease
and HCC such as blood transfusion, previous jaundice,
scarification mark and alcohol consumption, were ob-
tained using a structured questionnaire. ‘Heavy alcohol
intake’ was defined as a daily minimum consumption of
160 g alcohol for at least eight years, while cigarette
smoking was defined as 10 sticks per day for at least
10 years. Regular intake of native herbal preparations for
more than 10 years was considered herbal abuse. Diag-
nosis of HBV infection was based on positive serology
for HBsAg using a microparticle enzyme immunoassay
(MEIA) (Abbott Laboratories, AXSYM, United States).
Diagnosis of HCV infection was based on positivity for
anti-HCV antibodies, as determined by third-generation
enzyme immunoassay (Abbott Laboratories). HIV test-
ing was performed using the Tanzania HIV Rapid Test
Algorithm [15] and CD4+ count using FACS or
FACSCALIBUR (BD Biosciences, United States). A
determination of CD4+ count was only performed in
HIV-positive patients. HCC was diagnosed based on a his-
topathological examination. Cirrhosis was diagnosed
histologically in most cases. We could not estimate the
Alpha fetoprotein (AFP) levels or carry out computed
tomography (CT)scan on the patients due to the lack of
this equipment at our centre. The clinical stage of the dis-
ease was assigned to each patient using the Okuda classifi-
cation [16].
Statistical data analysis
The statistical analysis was performed using the Statis-
tical Package for Social Sciences (SPSS) version 17.0 for
Windows (SPSS, Chicago, Illinois, United States). The
median (and IQR) and ranges were calculated for con-
tinuous variables, whereas proportions and frequency ta-
bles were used to summarize categorical variables. The
chi-square (χ2) test was used to test for the significance
of association between the independent (predictor) anddependent (outcome) variables in the categorical vari-
ables. The level of significance was considered as P < 0.05.
Multivariate logistic regression analysis was used to deter-
mine predictor variables that predicted the outcome.
Ethical consideration
Ethical approval to conduct the study was obtained from
the CUHAS-Bugando/BMC joint institutional ethic re-
view committee before the commencement of the study.
Results
Sociodemographic data
Out of 3104 patients who were registered with malig-
nancies during the study period, 155 were histopatho-
logically confirmed cases of hepatocellular carcinoma.
Of these, 13 patients were excluded from the study due
to incomplete data. Thus, 142 patients representing 4.6%
of cases were enrolled into the study and this formed
the study population (Figure 1). Of these, 98 (69.0%)
were males and 44 (31.0%) were females with a male to
female ratio of 2.2: 1. The age of patients at diagnosis
ranged from 14 to 76 years with a median age of 45 years
and (IQR of 38 to 53 years). The modal age group was
41 to 50 years, accounting for 47.2% of cases (Table 1).
Patients with HBV-associated HCC presented at a youn-
ger age than those with HCV-associated HCC. This as-
sociation was statistically significant (P = 0.004). The
majority of patients (122, 85.9%) were farmers coming
from rural areas located a considerable distance from
the study area and more than 80% of them were
unemployed.
Etiological risk factors
Seventy-four (52.1%) patients stated a history of inges-
tion of foods stored in humid conditions (a likely sus-
pected source of aflatoxin B1 exposure). Eighty-five
(59.9%) patients had a past history of jaundice and 32
(22.5%) had scarification marks. The use of traditional
herbal concoctions was documented in 82 (57.7%) pa-
tients. A history of heavy alcohol consumption was re-
ported in 86 (60.6%) patients. A past blood transfusion
was documented in 28 (19.7%) patients.
Clinicopathological presentation
The duration of symptoms before presentation ranged
from 2 to 48 weeks with a median of 16 weeks and (IQR
of 12 to 20 years). The majority of patients (125, 88.0%)
had symptoms of more than 16 weeks duration at the
time of presentation. Table 2 shows the distribution of
patients according to clinical presentation.
A pre-existing medical illness was recorded in 9 (6.3%)
patients; diabetes mellitus in three patients, hypertension
in two patients, tuberculosis and chronic renal failure in
two patients each respectively.
Table 2 Distribution of patients according to clinical
Figure 1 Flow chart of patients.
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(23.1%) patients were known cases on antiretroviral ther-
apy (ARV) and the remaining 10 (76.9%) patients were
newly diagnosed patients.
According to the Okuda classification [16], the major-
ity of patients (76.8%) presented in stage III, while 23.2%
of patients presented in stage II. No patients presented
with stage I. Distant metastases were documented in 38
(26.8%) patients and occurred mainly to the lungs,
bones, and skin. The majority of patients, 75 (52.8%)
had both right and left lobe involvement. The left and
right lobes were involved in 42 (29.6%) and 25 (17.6%)
patients, respectively. The various histopathological
grades of the cancer included welldifferentiated HCC
(59.2%), anaplastic HCC (28.1%), and moderately dif-
ferentiated HCC (12.7%). The histological types were
trabecular and/or sinusoidal pattern (68 patients 47.9%),
pseudoglandular and/or acinar pattern (35 patients
24.6%), compact pattern (25 patients 17.6%), clear cell (9
patients 6.3%), and scirrhous and/or fibrolamellar (5
patients 3.5%). The presence of cirrhosis coexisting with
HCC was reported in 94 (66.2%) patients. The Child-Table 1 Sex distribution according to age group
Age group Male (N/%) Female (N/%) Total (N/%)
<20 5 (3.5) 1 (0.7) 6 (4.2)
21-30 8 (5.6) 6 (4.2) 14 (9.8)
31-40 10 (7.1) 7 (4.9) 17 (12.0)
41-50 45 (31.7) 22 (15.5) 67 (47.2)
51-60 19 (13.4) 7 (4.9) 26 (18.3)
61-70 8 (5.6) 1 (0.7) 9 (6.3)
>70 3 (2.1) 0 3 (2.1)
Total 98 (69.0) 44 (31.0) 142 (100)Pugh classification of stage of the disease is as shown in
Table 3.
Radiological and laboratory investigations
Abdominal ultrasonographic appearance performed in
all the HCC patients revealed multiple discrete lesions
(49.3%), diffuse lesions (26.6%), and solitary lesions
(14.1%). The size of the single focal lesion was greater
than 10 cm in 60.0% of patients, 5 to 10 cm in 25.0% of
patients, and only 15.0% of patients had a lesion less
than 5 cm.
Chest X-rays performed in 102 (71.8%) patients con-
firmed lung metastasis in 24 (23.5%) patients. No patient
had a computed tomography (CT) scan or magnetic res-
onance imaging (MRI) examination due to the lack of
these imaging facilities at our centre. Liver function tests
were performed in all patients and revealed abnormal re-
sults in 134 (94.4%) patients. Out of 142 patients, 94
(66.2%) tested positive for HBsAg, while anti-HCV anti-
bodies were detected in 24 (16.9%) patients. Elevenpresentation
Clinical presentation Frequency Percentages
Right upper abdominal pain 138 97.2
Weight loss 132 92.9






Hepatic bruit 18 12.7
Table 3 Distribution of patients according to demographic
and clinicopathological characteristics






















Multiple discrete lesions 70 49.3
Diffuse lesions 52 26.6
Solitary lesions 20 14.1
Solitary lesions
>10 cm 12 60.0
5-10 cm 5 25.0










Well differentiated 84 59.2
Moderately differentiated 18 12.7
Poorly differentiated 40 28.1




Hepatic encephalopathy 38 41.3
Massive hemoperitonium 23 25.0
Upper gastrointestinal bleeding 14 15.2
Hepatorenal syndrome 8 8.7
Bacterial peritonitis 5 5.4
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tients tested positive for HIV infection. The CD4+ count
among HIV-positive patients was available in only 8 pa-
tients and ranged from 122 to 788 cells/μl with a median
of 256 cells/μl. A total of three HIV-positive patients(37.5%) had a CD4+ count below 200 cells/μl and the
remaining five patients (62.5%) had a CD4+ count of
≥200 cells/μl.
Treatment modalities
All of our patients (100%) received supportive therapy
only because of the advanced nature of the disease and
general deteriorated condition. No patients received any
curative treatment such as liver transplantation, percu-
taneous ethanol ablation, or radio frequency ablation
due to the lack of these treatment modalities in our set-
ting and due the advanced nature of the disease at
presentation.
Outcome and follow-up of patients
Out of 142 patients, 92 developed complications giving a
complication rate of 64.8%. Of these, coagulopathy was
the most common complication, accounting for 45.7% of
cases (Table 4).
Sixty-six patients died in hospital, giving a mortality
rate of 46.5%. The median duration from the onset of
symptoms to time of death was 16 weeks (IQR of 12 to
20 weeks). According to multivariate logistic regression
analysis, associated comorbidity, HIV positivity, CD4+
count <200 cells/μl, high histological grade and ad-
vanced stage of the tumor, presence of metastases at the
time of diagnosis, and associated complications were the
main predictors of death (P < 0.001). The causes of the
deaths are shown in Table 5.
The length of hospital stay ranged from 6 to 45 days
with a median of 14 days (IQR of 10 to 16 days).
Out of 142 patients, 68 (47.9%) were discharged
aliveand a further 8 (5.6%) patients were discharged
against medical advice.
Patients were followed up on for a period of 12 months.
At the end of 12 months, only 22 (28.9%) patients (survi-
vors) were available for follow-up and the remaining 54
(71.1%) patients were lost to follow-up.
Discussion
Hepatocellular carcinoma is one of the most common
cancers in the world and is associated with poor progno-
sis [11-13]. According to recent reports, the incidence of
Table 5 Distribution of patients according to the causes
of death (N = 66)
Cause of death Frequency Percentage
Hepatic failure 34 55.5
Intraperitoneal bleeding 18 27.3
Hemorrhagic shock from variceal bleeding 16 24.2
Intra-tumor hemorrhage 11 16.7
Associated HIV complications 9 13.6
No established cause 12 18.2
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In this review, hepatocellular carcinoma accounted for
4.6% of all diagnosed malignancies seen during the study
period in our setting. A high figure of 5.6% was also re-
ported in one study in Turkey [18]. This may be related
to differences in diagnostic approaches and levels of ex-
posure to other carcinogenic or mutagenic environmen-
tal agents, such as aflatoxin B1.
In this study, HCC was more prevalent in males than
in females, with a male to female ratio of 2.2:1. This is in
agreement with other many studies [2,3,11-13,17,18].
The reasons for the male predominance may be ex-
plained in part by the differences in exposure to risk fac-
tors such as a higher prevalence of persistent HBV
infection, alcohol abuse, groundnut chewing, and smok-
ing in men than in women [19]. Genetic and hormonal
factors may also be important [20-22]. It has been spec-
ulated that estrogens and androgens could modulate
hepatocarcinogenesis and explain the higher incidence
of HCC in men [23].
Studies in developing countries have shown that HCC
tends to afflict people in their third and fourth decades
of life, unlike in developed countries where the disease is
prevalent in the older population [17]. In agreement
with other studies [11,12,17,18,24], the peak age of inci-
dence of hepatocellular carcinoma in our study was
found to be in the fourth decade of life, which is about a
decade or two earlier compared to the findings in devel-
oped countries. The occurrence of HCC in a younger
age group compared to the Western population suggests
an early exposure to carcinogenic factors in our patients.
We noted a tendency for patients with HBV-associated
HCC to present at a younger age than those with HCV-
associated HCC, which is in line with previous observa-
tions [25]. We could not establish the reason for this
occurrence.
Hepatocellular carcinoma has been reported in most
studies to be more prevalent in people with low socio-
economic status [2,3,13]. This finding is reflected in our
study in which the majority of patients were farmers
coming from rural areas located a considerable distance
from the study area and more than 80% of them were
unemployed. Similar observations were reported byother studies in developing countries [2,3,13,17,26]. This
observation has an implication on the accessibility of
healthcare facilities and awareness of the disease.
The major risk factors for developing hepatocellular
carcinoma vary by region and degree of national devel-
opment [26,27]. In the present study, HBV infection was
the most common etiological factor in our environment
as more than 65% of patients tested positive for HBsAg,
which is consistent with the findings of other studies
[2,3,11-13,18,26,27]. On other hand, only 16.9% of the
patients were positive for the HCV antibody which indi-
cates that HCV is not as important as HBV in the eti-
ology of HCC in this environment. This is contrary to
what occurs in the United States, Europe, and Japan
where 50 to 75% of patients with HCC had evidence of
HCV infection [28-30]. The high HBV seroprevalence
among patients with HCC in our setting calls for includ-
ing HBV vaccination in the national program on immu-
nization in Tanzania.
In this study, HBsAg were negative in 33.8% of the
HCC patients suggesting exposure to other strong etio-
logical factors such as aflatoxins and alcohol abuse. Ex-
posure to alcohol abuse was particularly high in this
study (60.6%). Possible exposure to aflatoxin B1, though
not proven as no test was conducted to incriminate it, is
highly suspected as a causative factor in this study as
52.1% of the patients were exposed to a likely source of
aflatoxin B1 contamination (inappropriately preserved
food). The duration of exposure to this could not be
ascertained. The ingestion of herbal preparations for
various ailments is widespread in Tanzania and more
than half of the patients in this study abused various
herbal preparations. Furthermore, the use of medicinal
herbs was reported as an important co-factor with afla-
toxin in the development of HCC in Ethiopia [31].
The prevalence of HIV infection among patients with
HCC in the present study was 9.2% which is higher than
the 6.5% [32] in the general population in Tanzania.
However, the overall HIV seroprevalence in this study
may actually be an underestimate and the magnitude of
the problem may not be apparent because many patients
were excluded from the study due to a failure to meet
the inclusion criteria. We could not establish the reason
for the high seroprevalence of HIV among these patients
although it is possible that these patients have an in-
creased risk of exposure to HIV infection. This calls for
further research on this observation. HIV infection was
found to be associated with poor outcome and this find-
ing call for routine HIV screening in patients suspected
to have HCC.
The clinical presentation of hepatocellular carcinoma
in our patients is not different from those in other stud-
ies [3,11,12], with right hypochondrial pain, weight loss,
and abdominal swelling being the commonest symptoms
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enlarged liver is considered a reliable diagnostic sign.
However, this sign was elicited in only 12.7% of the pa-
tients which is similar to what was reported by Ndububa
et al. [11] in Nigeria. This presentation generally reflects
the problem of late presentation that is common in
Tanzanian patients.
The majority of patients in this study presented late
with an advanced stage of the disease which is in keep-
ing with other studies performed in developing countries
[2,3,11-13,18,26,27]. The late presentation in our study
may be attributed to lack of awareness of the disease, a
lack of accessibility to healthcare facilities, and a lack of
advanced diagnostic investigations such as CT and MRI
scans in this region. The late presentation of cases is an
area of cancer care in our center that requires urgent at-
tention. Detecting primary cancer at an early stage con-
tributes to improved chances for successful treatment
and thus for survival.
Distant metastases were documented in 26.8% of the
patients and occurred mainly to the lungs, bones, and
skin. This figure is higher than that reported in other re-
ports [3,11,12,26]. The high rate of distant metastases in
this study is attributed to the late presentation in the
majority of patients and this confirmed the highly meta-
static potential of HCC.
It was found in this study that the majority of patients
(52.8%) had both right and left lobe involvement,
whereas the left and right lobes were involved in 29.6%
and 17.6% of the patients respectively. This was contrary
to the findings in the study of El-Zayadi et al. [17] who
found 65% affecting the right lobe, 13.4% the left lobe,
and 21.6% affecting both lobes. We could not establish
the reason for this anatomical distribution. Histopatho-
logically, the trabecular type was the most commonly
encountered variety. This finding is similar to that noted
by most other researchers; the trabecular type being re-
ported to be the most common type and constituting 60
to 75% of HCC [33].
The presence of cirrhosis coexisting with HCC was re-
ported in 66.2% of the patients, which is in agreement
with the figure of 60 to 100% reported in literature [16].
Globally, more than 80% of HCC cases occur in individ-
uals with cirrhosis of the liver [34], and the annual inci-
dence of HCC in cirrhotic patients is 1 to 6% [18,35].
This suggests that cirrhosis is the main risk factor for
this tumor.
The ultrasonographic appearance of HCC performed
in all patients concurs with what was described by
Nwokediuko et al. [36] in Nigeria. Multinodular HCC is
known to be more prevalent in patients with multiple
risk factors for this cancer [37]. This suggests that the
risk factors for most of our patients with HCC may be
multiple.The treatment of HCC requires a multidisciplinary ap-
proach. Treatment modalities of HCC include surgery in
the form of either resection or transplantation, locore-
gional therapy including transarterial chemoemboliza-
tion, percutaneous ethanol injection, or radiofrequency
ablation. These techniques may be curative in patients
with early stage of the disease. However, these tech-
niques have yet to be used on a large scale in Sub-
Saharan Africa, including Tanzania, and no reports of
the results obtained have been published. The treatment
of HCC in resource-limited countries like ours has been
and remains largely unrewarding. Late presentation and
the advanced stage of the disease at the time of diagno-
sis, as well as inadequate diagnostic and treatment facil-
ities for the tumor pose enormous challenges in
managing HCC in these countries [13]. Surgery in the
form of either resection or transplantation is currently
the only golden standard treatment for HCC with cura-
tive potential [3,13]. However, curative surgery in most
developing countries is limited because most of the pa-
tients we see in our environment present late with an
advanced stage of the disease at the time of diagnosis,
for which only palliative treatment is possible. This fact
is reflected in our study as all of our patients received
supportive therapy only because of the advanced nature
of the disease and general deteriorated condition. Late
presentation still poses a challenge to the successful
management of HCC in our setting and requires public
education.
As reported by Mustapha and Pindiga [12] in Nigeria,
coagulopathy was the most common complication in
this study, occurring in 45.7% of the patients. Therefore,
it is important to do the clotting profile of all HCC pa-
tients, especially if needle biopsy of the liver is being
contemplated, in order to ovoid continuous bleeding
from the biopsy site.
The overall mortality rate in this study was 46.5%, a
figure which is higher than that reported by Salem et al.
[26] in Yemen. The mean duration from onset of symp-
toms to time of death was 16 weeks, which is in agree-
ment with the findings from other studies [11,12,38].
Hepatic failure and intraperitoneal hemorrhage were the
most common causes of death. In this study, the mortal-
ity rate was significantly high in patients with associated
comorbidity, HIV positivity, CD4+ count <200 cells/μl,
high histological grade and advanced stage of the tumor,
presence of metastases at the time of diagnosis, and as-
sociated complications. Addressing these factors respon-
sible for high mortality in our patients is mandatory to
be able to reduce mortality associated with this disease.
The overall median duration of hospital stay in the
present study was 14 days which is higher than that re-
ported by Ajayi et al. [39] in Nigeria. However, due to
the poor socioeconomic conditions in Tanzania, the
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than expected.
In keeping with other studies [11,12], the outcome of
patients in the present study was generally poor, as less
than 50% of patients were discharged alive. This is not
surprising because the prognosis of HCC all over the
world is generally poor. The reasons for the poor out-
come in our HCC patients may be attributable to late
presentation so that the majority of patients had an ad-
vanced stage of the disease at presentation.
Self-discharge by the patient against medical advice is
a recognized problem in our setting. In this study, 5.6%
of patients were discharged against medical advice. A
high figure of 9.4% was reported by Ajayi et al. [39]
inNigeria. We could not establish the reasons for this
difference.
The follow-up of patients in this study was generally
poor as more than 70% of patients were lost to follow-
up at the end of the follow-up period. This observation
concurs with other studies performed in developing
countries [2,11,13,38]. Poor follow-up of patients in our
study remain a cause for concern. The loss to follow-up
after hospital discharge may be the result of poverty, the
long distance from the hospital centers, and ignorance.
The potential limitation of this study is the fact that
information about some patients was incomplete in view
of the retrospective nature of the study and this might
have introduced some bias in our findings. However,
despite this limitation, the study has provided local data
that can help healthcare providers in the management of
patients with HCC. The challenges identified in the
management of HCC in our setting need to be addressed
in order to deliver optimal care for these patients.
Conclusions
Hepatocellular carcinoma patients in this region are
relatively young at diagnosis and the majority of them
present late with an advanced stage of the disease and a
high rate of distant metastasis. Hepatitis B virus infec-
tion and alcohol abuse are the most common etiological
factors in our environment. Lack of awareness of the
disease, poor accessibility to healthcare facilities, lack of
diagnostic facilities, the high cost of care, and a high
morbidity and mortality rate are among the hallmarks of
the disease in this region and pose a great challenge in
the management of these patients. Therefore public en-
lightenment, early diagnosis, and effective cost-effective
treatment and follow-up will help reverse this trend. In
addition, early HBV immunization of all children will go
a long way towards reducing the incidence of HCC in
later life.
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